Our cellular studies suggest that, despite being a potent activator of cGMP in C6 glioma cells, the use of CNP as one such cGMP-elevating therapy may well be compromised by the inhibitory effects that hyperammonemia has on GC-B function. Here, NPR2 is linked to glioma.